Global Smart Biosensors Market: Information by Product Type (Wearable Biosensors, Non-wearable Biosensors), Technology (Electrochemical Biosensors, Others), Application (Drug Discovery, Others), End User (Point-Of-Care & Others)—Global Forecast till 2023
Market Scenario:
Biosensors are analytical devices used for detection of chemical and biological substances in the human body. Smart biosensors are easy to use, simple, accurate and effective than traditional methods of analysis. Biosensors are becoming popular in developed countries. The increasing prevalence of diabetes in emerging economies, demand for advanced monitoring systems, and increasing awareness about advance biosensors are expected to drive the growth of the market. According to the report published by World Health Organization(WHO) in 2016, diabetes is a major healthcare concern in Brazil, and it affected more than 8.1% of the population, the prevalence of diabetes was more in females, and it affected more than 8.8% females in the country. Moreover, rising R&D spending and collaborative strategies adopted by the top players such as new product launches and collaborations for product development are contributing to the growth of the market.
The Global Smart Biosensors Market accounted for USD 12000 million and expected to register 7.64% CAGR during the forecast period (2018–2023)
The rising cost of biosensors and unfavorable reimbursement policies may hamper the growth of the market during the assessment period.
Top Key Players
- Abbott Point of Care Inc.,
- Medtronic Inc.,
- Hoffman La-Roche Ltd.,
- Siemens Healthcare AG,
- Lifescan, Inc.,
- LifeSensors Inc.,
- Nova Biomedical Corp.,
- Acon Laboratories Inc.,
- Universal Biosensors,
- Pharmaco-Kinesis Corporation,
Segmentation
The global smart biosensors market has been segmented on the basis of product type, technology, application, and end user.
On the basis of product type, the market has been classified as wearable biosensors, non-wearable biosensors.
The technology segment has been divided into electrochemical biosensors, piezoelectric biosensors, optical biosensors, thermal biosensors, nanomechanical biosensors, and others. thermal biosensors segment is likely to be the fastest growing segment during the forecast period.
The market, by application, has been segmented into blood glucose testing, cholesterol testing, blood gas analysis, pregnancy testing, drug discovery, infectious disease testing, and others.
The end user segment has been divided into point-of-care, home diagnostics, research labs, security & biodefense, environmental monitoring, food & beverage industry, and others
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The smart biosensors market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European smart biosensors market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The smart biosensors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The smart biosensors market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas are expected to hold the maximum share of global smart biosensors market owing to the rising prevalence of chronic disorders, favorable policies implemented by government and regulatory authorities, and adoption of highly advanced technology. According to the article published in 2016 by National Council on Aging, the prevalence of Chronic disorders in American regions is continuously increasing and about 80 percent of older adults have at least one chronic disease, and more than 68 percent were suffering from more than one chronic disorders.
The European market is likely to be the second-largest smart biosensors market. The market growth in this region can be attributed to the presence of well-established healthcare system in the region, government initiatives for controlling chronic disorders, and increase in the population suffering from cardiovascular disorders. According to the European Heart Network, cardiovascular disorders are responsible for 3.9 million deaths in the European Union which are 45% of the total deaths.
Asia-Pacific is expected to be the fastest-growing smart biosensors market during the forecast period owing to the increasing prevalence of diabetes, increasing disposable income, and government initiatives for the development of the healthcare sector. According to the International Diabetes Federation, in 2017, more than 84 million people in South-East Asia were affected by diabetes, and this number is expected to reach 156 million by 2045.
The market in the Middle East & Africa is expected to hold the smallest share of the global smart biosensors market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Browse More Healthcare Reports @